Successful Treatment of a Patient With Epstein-Barr Virus–Positive B-Cell Lymphoproliferative Disorder Resembling Post-Transplant Lymphoproliferative Disorder Using Single-Agent Rituximab
- 1 August 2011
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (22), e658-e660
- https://doi.org/10.1200/jco.2011.34.8656
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Epstein-Barr Virus–Positive Diffuse Large B-Cell Lymphoma of the Elderly: What We Know So FarThe Oncologist, 2011
- Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 studyBlood, 2006
- Epstein-Barr virus: the impact of scientific advances on clinical practiceBlood, 2006
- Efficacité du Rituximab au cours d’une granulomatose lymphomatoïdeRevue des Maladies Respiratoires, 2004
- Successful Treatment of Systemic and Central Nervous System Lymphomatoid Granulomatosis with RituximabLeukemia & Lymphoma, 2004
- Senile EBV+ B-Cell Lymphoproliferative DisordersThe American Journal of Surgical Pathology, 2003
- Diagnosis and Management of Posttransplant Lymphoproliferative Disorder in Solid‐Organ Transplant RecipientsClinical Infectious Diseases, 2001
- Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantation: a report of three casesJournal of Hepatology, 2000
- Transformation of foetal human leukocytes in vitro by filtrates of a human leukaemic cell line containing herpes‐like virusInternational Journal of Cancer, 1968
- VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMAThe Lancet, 1964